Selonsertib

Drug Profile

Selonsertib

Alternative Names: ASK1 inhibitor - Gilead Sciences; GS-4977; GS-4997

Latest Information Update: 03 Jan 2017

Price : $50

At a glance

  • Originator Gilead Sciences
  • Class Cardiovascular therapies
  • Mechanism of Action MAP kinase kinase kinase 5 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alcoholic hepatitis; Diabetic nephropathies; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Pulmonary arterial hypertension

Most Recent Events

  • 01 Dec 2016 Gilead Sciences completes the phase II ARROW trial in Pulmonary arterial hypertension in USA, United Kingdom, the Netherlands, Canada, France, Germany, Italy and Spain (NCT02234141)
  • 11 Nov 2016 Gilead Sciences completes a phase II trial in Non-alcoholic steatohepatitis (Combination therapy) in Canada and USA (PO) (NCT02466516)
  • 26 Oct 2016 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top